Moxifloxacin is a quinolone antibiotic often used to treat infections caused by Gram positive bacteria that have developed resistance in Columbia in recent years. This study was designed to evaluate the concentration of the main active ingredient in moxifloxacin antibiotic formulations through high performance liquid chromatography (HPLC). It also determined the antibiotic activity through the minimum inhibitory concentration (MIC) of generic versions of moxifloxacin and its brand-name equivalent, against strains of Staphylococcus aureus and Escherichia coli bacteria isolated from hospitalized patients, American Type Culture Collection (ATCC) bacterial strains that are both sensitive and resistant, and isolates from MICROKIT SL Laboratories. It has been found that the concentrations of the main active ingredient in both generic and commercial medications are in the range established by the United States Pharmacopeia (USP) 38, required for the submission of injectable moxifloxacin 400 mg/250mL. The results for the MIC of both generics alternative and USP standard of Moxifloxacin were 0.125 µg/mL, 4 µg/mL, and 0.008 µg/mL for resistant S. aureus, ATCC and tropical E. coli bacteria respectively. Here, both generic products showed similar MIC values on all bacteria evaluated.
Subscribe now to GaBI Journal to view full information of this article to be published in the next journal issue.